Logo
x

Search

Subscribe Now

RESONATE-2

PharmaShots Interview: Janssen's Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

PharmaShots Interview: Janssen's Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

  • July 19, 2021
AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

  • December 8, 2020
Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia

Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia

  • December 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.